Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial
在不可切除的 III 期非小细胞肺癌患者中,序贯放化疗后使用度伐利尤单抗治疗——来自 II 期 PACIFIC-6 试验的最终分析
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105071
Garassino, M C; Khalifa, J; Reck, M; Chouaid, C; Bischoff, H; Reinmuth, N; Cove-Smith, L; Mansy, T; Cortinovis, D L; Migliorino, M R; Delmonte, A; Garcia Sánchez, J; Chara Velarde, L E; Bernabe, R; Paz-Ares, L; Chander, P; Diaz Perez, I; Foroutanpour, K; Emeribe, U; Faivre-Finn, C